Inovio Pharmaceuticals, Inc.
INO · NASDAQ
Market closed$1.12$0.00 (0.00%)After hours $1.13 · +0.89%
Key statistics
Previous close$1.12
Open$1.12
Day high$1.15
Day low$1.10
52-week high$2.98
52-week low$1.03
Market cap60.02M
Volume824.05K
Average volume2.30M
P/E ratio-1.10
Forward P/E—
EPS-1.02
Dividend yield0.00%
Market context
Why it moved
INO traded flat today as the earlier speculative rally driven by Trump's hantavirus outbreak comments and Inovio's historical hantavirus DNA vaccine research faded, leaving the stock consolidating with no new catalysts to sustain momentum.
What is happening
Recent company-specific developments and publisher coverage.
PR Newswire · May 13, 2026INOVIO Reports First Quarter 2026 Financial Results and Recent Business HighlightsSimply Wall Street · May 10, 2026Is Inovio (INO) Turning Fresh DNA Medicine Data Into a More Coherent Investment Story?PR Newswire · April 2, 2026INOVIO Announces Pricing of $17.5 Million Public OfferingPR Newswire · March 12, 2026INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Mt Newswire · July 2, 2026Inovio Pharmaceuticals Files $300 Million Mixed Shelf Offering Benzinga · July 2, 2026Inovio Pharmaceuticals May Offer Up To $300 Mln Of Securities Mt Newswire · May 21, 2026Inovio Says China Partner Reported VGX-3100 Phase 3 Trial Met Primary Efficacy Endpoint in Cervical Dysplasia Patients Benzinga · May 21, 2026Inovio Pharmaceuticals' Partner For VGX-3100 In China, ApolloBio, Announces Topline Results From Its Pivotal Phase 3 Trial Of VGX-3100; Trial Met Its Predefined Primary Efficacy Endpoint And Demonstrated An Overall Favorable Safety And Tolerability Profile Benzinga · May 13, 2026Full Transcript: Inovio Pharmaceuticals Q1 2026 Earnings Call Benzinga · April 7, 2026What's Going On With Inovio Pharmaceuticals Stock On Tuesday? Benzinga · April 2, 2026What's Behind The Drop In Inovio Pharmaceuticals Stock Today? Mt Newswire · April 2, 2026Inovio Pharmaceuticals Prices $17.5 Million Public Offering